VIRPAX PHARMACEUTICALS, INC.

Insiders Virpax Pharmaceuticals, Inc.

Equities

VRPX

US9282512063

Market Closed - Nasdaq Other stock markets 21:30:01 13/05/2024 BST			5-day change	1st Jan Change
3.04 ^USD	+19.22%		+31.60%	-5.03%

04-30	Virpax Pharmaceuticals, Inc. Announces Results of Maximum Tolerated Dose Study for Probudur	CI
03-26	Virpax Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	CI

Insiders

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Virpax Pharmaceuticals Announces Leadership Transition	11-17	CI
Virpax Pharmaceuticals, Inc. Announces CEO Changes	11-16	CI
Virpax Names Gerald Bruce as CEO of Novvae Pharmaceuticals Unit	02/10/23	MT
Novvae Pharmaceuticals Announces Executive Appointments	02/10/23	CI
Virpax Pharmaceuticals Names New CFO	20/06/23	MT
Virpax Pharmaceuticals, Inc. Announces Executive Changes	20/06/23	CI
Virpax Pharmaceuticals, Inc. Appoints Barbara Ruskin as Class I Director	07/06/23	CI
Virpax Pharmaceuticals Announces Appointment of Barbara A. Ruskin to the Board of Directors	28/03/23	CI
Virpax Pharmaceuticals, Inc. Announces Board Appointments	30/07/21	CI
Virpax Pharmaceuticals, Inc. Promotes Michèle C. Linde to EVP, Global Corporate Governance, Chief Legal Officer & Corporate Secretary	22/10/19	CI
Virpax Pharmaceuticals, Inc. Appoints Gerald W. Bruce as Executive Vice President, Commercial Operations	17/09/19	CI
Virpax Pharmaceuticals, Inc. Announces Board Appointments	10/09/19	CI
Virpax Pharmaceuticals, Inc. Appoints Michèle C. Linde as the Executive Vice President, General Counsel and Corporate Secretary	11/06/19	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

As early as today, start finding the best investment opportunities!

Optimize my profits

fermer